24 September 2025
Economic Evaluation of Prime-Boost HIV vaccine (ALVAC-HIV® and AIDSVAX B/E®) for the Thai population (in Thai language)
View Count
42
Share this research
Project Code
02-302-2552
Country
Thailand
Project Duration
Start : 1 January 2009
Research Status
Completed 100%
Complete Research Report
Quantity 1 files
Download Count
0 times
24 September 2025
Economic Evaluation of Prime-Boost HIV vaccine (ALVAC-HIV® and AIDSVAX B/E®) for the Thai population (in Thai language)
About Project
Content
A cost-utility analysis was performed to estimate the costs and quality adjusted life year (QALY) of HIV prevention program compared to only existing programs. This analysis focused on both the general population and high risk populations. This study found that the incremental cost effectiveness ratio of HIV vaccination was most sensitive to change in risk behaviors at the post-vaccination period. If postvaccination risk behavior remained unchanged, HIV vaccination for high risk populations would be more cost-effective than for the general population.
Research Type
Others
Related Technologies
Pharmaceuticals
Funding Source
Health Systems Research Institute (HSRI)
Research Team
Principal Researcher
Related Organizations/
Supporting Organizations
Health Systems Research Institute (HSRI)
